申请人:Albert Rolland S.A.
公开号:US04259509A1
公开(公告)日:1981-03-31
This invention relates to compounds having the formula: ##STR1## which represents the isomer Z, the isomer E or the mixture of both stereoisomers of the oximino group and in which: A represents O or S, X.sup.1 represents a halogen atom, a hydrogen atom or a methyl group, R represents a hydrogen atom or a C.sub.1-5 alkyl group, X.sup.2 and X.sup.3, which may be the same or different, represent each a hydrogen atom, a halogen atom or a C.sub.1-5 alkyl group, and R' represents a hydrogen atom or a C.sub.1-5 alkyl group, and the group ##STR2## is at 2- or 3-position on the heterocycle, and the salts of acids of the formula (I) with physiologically acceptable bases, and the compounds which are metabolically converted to compounds of the formula (I). Said compounds are therapeutically useful, typically as hypocholesterolemic, hypolipemic and uricosuric agents.
本发明涉及具有以下式子的化合物:##STR1## 其中,代表氧肟基的顺反异构体Z、E或两种立体异构体的混合物;其中:A代表氧或硫,X1代表卤素原子、氢原子或甲基基团,R代表氢原子或C1-5烷基基团,X2和X3可以相同或不同,分别代表氢原子、卤素原子或C1-5烷基基团,R'代表氢原子或C1-5烷基基团,而且上述式子中的基团##STR2## 在杂环上的2-或3-位置上,以及公认为生理上可接受的碱的酸盐和代谢转化为式(I)化合物的化合物。这些化合物在治疗上有用,通常作为降低胆固醇、降低脂肪和尿酸排泄剂。